Weekly Roundup: With great power comes a place on the Medicine Maker Power List. Optimum’s clients have the power.
ReBio Pharma appointed leading ocular oncologist Professor Mandeep Sagoo as Chief Medical Officer
ReBio Pharma, a biotechnology company developing novel, targeted, eye- and vision-preserving therapies for ocular oncology, announced the appointment of Professor Mandeep Sagoo, MB, PhD, FRCS (Ed), FRCOphth, as Chief Medical Officer (CMO). In this role, Professor Sagoo will lead ReBio’s clinical and medical strategy and build its clinical development capabilities as the Company advances RBP-01, its lead programme for primary uveal melanoma, into the clinic.
Hansa Biopharma reported Second Quarter and first Half Year 2026 Financial Results
Hansa Biopharma AB announced its half year report for the period January-June 2026. Q2 delivered a €115 million out-licensing agreement with SERB for Idefirix, positive data from the European confirmatory PAES trial, and continued progress toward a potential US launch, strengthening Hansa’s financial and strategic position moving into the second half of the year.
R1 Therapeutics announced commencement of global Phase 2b trial of AP306 for hyperphosphatemia in patients on dialysis
R1 Therapeutics, Inc, a clinical-stage biopharmaceutical company developing first-in-class therapies for patients with kidney disease, announced that the first patient has been randomised in its global Phase 2b trial of AP306, a first-in-class pan phosphate transporter inhibitor in development as a monotherapy for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.
Poolbeg Pharma plc – Notice of Allowance received for Israeli patent for POLB 001
Poolbeg Pharma, a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announced that it has received a Notice of Allowance from the Israeli Patent Office for POLB 001 in cancer immunotherapy-induced Cytokine Release Syndrome.
Advanced Medical Solutions Group plc announced Half Year 2026 Trading Update
Advanced Medical Solutions Group plc (AIM: AMS), the innovative tissue-healing medical device company delivering high-performing solutions for better patient outcomes, announced a trading update for the six months ended 30 June 2026, with half year 2026 revenues expected to be approximately £115.2 million (H1 2025: £110.8 million).
👥Industry events
Optimum’s 18th Annual Healthcare Investor Conference – London | 8th Oct 2026
We have announced the first fireside chat at our Conference will be between Professor Edith Heard, FRS, Director and CEO of the Crick Institute and Clive Cookson, Senior Science Writer of the Financial Times. More details will be released in due course. Follow us on LinkedIn to hear updates on speakers, as they are announced.
Maximising Europe’s Potential – The theme of Optimum’s Annual Healthcare Investor Conference 2026.
The invitation only event takes place on Thursday 8th October and features leading speakers from the healthcare and investment communities. Register your interest in attending today: https://www.optimumcomms.com/irconference2026/
BIO-Europe 2026 – Cologne, Germany | 9–11th Nov 2026
Connecting with the global biotech community – Our CEO, Mary Clark, and Associate Director Zoe Bolt will be attending BIO-Europe 2026, one of the leading international partnering events for the life sciences industry.
The team look forward to meeting with companies, investors and potential partners to discuss collaboration opportunities. Get in touch to schedule a get-together.
Plan ahead for Europe’s busiest week in healthcare 🌍
Jefferies Global Healthcare Conference & Life Sciences Week – London | 15–20th Nov 2026
Join the mailing list to receive the official networking event guide, produced by Catalyst Advisors and Optimum Strategic Communications in partnership with Jefferies.
That’s all folks! To stay in the know – subscribe to Optimum’s weekly wrap-up today!
